Breaking Down SG&A Expenses: AstraZeneca PLC vs TG Therapeutics, Inc.

A Tale of Two Companies: AstraZeneca vs. TG Therapeutics

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry giants like AstraZeneca PLC and emerging players such as TG Therapeutics, Inc. is crucial. Over the past decade, AstraZeneca has consistently allocated a significant portion of its budget to Selling, General, and Administrative (SG&A) expenses, peaking at approximately $18 billion in 2022. This represents a 90% increase from 2016, highlighting their aggressive market strategies and expansive operations.

Conversely, TG Therapeutics, a smaller biotech firm, has shown a more modest yet steady increase in SG&A expenses, reaching around $123 million in 2023. This growth, over 900% since 2014, underscores their commitment to scaling operations and enhancing market presence. The stark contrast in SG&A spending between these two companies offers a fascinating glimpse into their strategic priorities and market positioning.